The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank.

MLA

Hydes, Theresa J., et al. “The Impact of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis on Adverse Clinical Outcomes and Mortality in Patients with Chronic Kidney Disease: A Prospective Cohort Study Using the UK Biobank.” BMC Medicine, vol. 21, no. 1, May 2023, pp. 1–13. EBSCOhost, https://doi.org/10.1186/s12916-023-02891-x.

APA

Hydes, T. J., Kennedy, O. J., Buchanan, R., Cuthbertson, D. J., Parkes, J., Fraser, S. D. S., & Roderick, P. (2023). The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank. BMC Medicine, 21(1), 1–13. https://doi.org/10.1186/s12916-023-02891-x

Chicago

Hydes, Theresa J., Oliver J. Kennedy, Ryan Buchanan, Daniel J. Cuthbertson, Julie Parkes, Simon D. S. Fraser, and Paul Roderick. 2023. “The Impact of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis on Adverse Clinical Outcomes and Mortality in Patients with Chronic Kidney Disease: A Prospective Cohort Study Using the UK Biobank.” BMC Medicine 21 (1): 1–13. doi:10.1186/s12916-023-02891-x.